- Home
- KYMR vs DCI Comparison
KYMR vs DCI Comparison
Compare KYMR & DCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KYMR | DCI |
|---|---|---|
| Founded | 2015 | 1915 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Pollution Control Equipment |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 10.6B |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | KYMR | DCI |
|---|---|---|
| Price | $110.28 | $92.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 26 | 5 |
| Target Price | ★ $107.72 | $99.00 |
| AVG Volume (30 Days) | ★ 682.9K | 653.3K |
| Earning Date | 04-30-2026 | 06-02-2026 |
| Dividend Yield | N/A | ★ 1.38% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.75 |
| Revenue | $39,211,000.00 | ★ $2,844,900,000.00 |
| Revenue This Year | $10.61 | $4.58 |
| Revenue Next Year | $8.17 | $5.18 |
| P/E Ratio | ★ N/A | $33.74 |
| Revenue Growth | N/A | ★ 4.05 |
| 52 Week Low | $36.88 | $70.17 |
| 52 Week High | $130.05 | $112.84 |
Technical Indicators
Market Signals| Indicator | KYMR | DCI |
|---|---|---|
| Relative Strength Index (RSI) | 54.52 | 64.14 |
| Support Level | $108.87 | $85.48 |
| Resistance Level | $120.90 | $94.26 |
| Average True Range (ATR) | 5.47 | 1.91 |
| MACD | -1.68 | 0.13 |
| Stochastic Oscillator | 22.52 | 84.05 |
Price Performance
Historical ComparisonAbout KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
About DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts, including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors. The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.7 billion in revenue in its fiscal 2025.